Pitavastatin is indicated for the following cases-

• Hyperlipidemia
• Prevention of Cardiovascular diseases (myocardial infarction, stroke, angina etc.)
• Coronary heart diseases

Hyperlipidemia

Prevention of Cardiovascular diseases

Coronary Heart Disease

• PITAVASTATIN is available as Tablets of- 1 mg, 2 mg, and 4 mg.
• PITAVASTATIN is taken orally once daily with or without food at the same time each day.
• The dose of PITAVASTATIN should be individualized according to patient characteristics, goal of therapy, and response.
• After initiation or upon titration, analyze lipid levels after 4 weeks and adjust the dosage accordingly.
• The recommended starting PITAVASTATIN dosage is 2 mg once daily.
• The maximum recommended dosage is PITAVASTATIN 4 mg once daily
• The recommended starting dosage for patients with moderate and severe renal impairment (estimated glomerular
• filtration rate 30-59 and 15-29 mL/min/1.73 m2, respectively) as well as end-stage renal disease on hemodialysis is PITAVASTATIN 1 mg once daily and the maximum dose is 2 mg once daily 
• Patients taking erythromycin, should not exceed 1 mg once daily  while patients taking rifampin, should not exceed 2 mg once daily 

Side effects associated with the use of PITAVASTATIN include-

• Hepatic dysfunction
• myalgia
• muscle spasm
• headache
• dizziness
• influenza
• nasopharyngitis
• insomnia

Hepatic dysfunction	Myalgia	Headache
Dizziness	Nasopharyngitis	Insomnia (Difficulty in Falling asleep)

• PITAVASTATIN may cause myopathy (muscle pain, tenderness, or weakness with creatine kinase (CK) above ten times the upper limit of normal) and rhabdomyolysis (with or without acute renal failure secondary to myoglobinuria). Rare fatalities have occurred as a result of rhabdomyolysis with statin use, including PITAVASTATIN.
• There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment
• Increases in serum transaminases have been reported with PITAVASTATIN. In most cases, the elevations were transient and either resolved or improved on continued therapy or after a brief interruption in therapy.  There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including PITAVASTATIN.
• Increases in HbA1c and fasting serum glucose levels have been reported with statins, including PITAVASTATIN.